GSK (GSK) to Release Quarterly Earnings on Wednesday

GSK (NYSE:GSK) is expected to release its earnings data before the market opens on Wednesday, February 5th. Analysts expect GSK to post earnings of $0.44 per share and revenue of $7.75 billion for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

GSK Price Performance

Shares of NYSE GSK opened at $35.12 on Wednesday. The stock’s 50-day simple moving average is $33.94 and its 200-day simple moving average is $37.78. The firm has a market capitalization of $72.78 billion, a PE ratio of 22.80, a price-to-earnings-growth ratio of 1.31 and a beta of 0.63. GSK has a fifty-two week low of $31.72 and a fifty-two week high of $45.92. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.53 and a current ratio of 0.81.

Analyst Ratings Changes

Several analysts have recently weighed in on GSK shares. Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Jefferies Financial Group downgraded shares of GSK from a “buy” rating to a “hold” rating and decreased their price objective for the company from $53.00 to $39.50 in a research note on Tuesday, November 12th. StockNews.com downgraded GSK from a “strong-buy” rating to a “buy” rating in a report on Tuesday, January 21st. Finally, Guggenheim downgraded GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Six research analysts have rated the stock with a hold rating, one has assigned a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, GSK presently has an average rating of “Moderate Buy” and an average target price of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.